BIND Therapeutics, Inc. (NASDAQ: BIND) disclosed that it opted to file for a voluntary petition under Chapter 11 of the Bankruptcy Code in the Bankruptcy Court for the District of Delaware in the ...
A pair of struggling drug developers—BIND Therapeutics and NephroGenex—today said they have filed for Chapter 11 bankruptcy protection from creditors. BIND said in a regulatory filing that it entered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback